医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Hoya Reports First Quarter Financial Results

2016年07月29日 PM08:24
このエントリーをはてなブックマークに追加


 

TOKYO

HOYA Corporation (TOKYO: 7741) today announced financial results for the first quarter ended June 30, 2016. During the quarter, revenues totaled 115,165 million yen, representing a decline of 8.8% year on year. Pre-tax profit was 22,274 million yen, and profit for the quarter amounted to 17,978 million yen, representing declines of 27.9% and 24.0%, respectively. This is in part due to a loss on foreign exchange of 3.4 billion yen compared with a gain on foreign exchange of 2.0 billion yen in the same period last year.

In the Information Technology segment, mask blanks for semiconductors increased in revenues, however, due to the earthquake damage to the Kumamoto plant, production of photomasks decreased. The volume of glass substrates for HDDs declined because of market conditions, and orders for imaging-related products decreased because of the Kumamoto earthquakes and other factors. These conditions, combined with the effects of appreciation of the yen, led to a drop in revenues for the IT segment as a whole.

In the Life Care segment, revenues in the eyeglass lens business in Europe and the United States increased, but due to the effect of appreciation of the yen, overall revenues in this business declined. Although contact lenses and intraocular lenses businesses held firm, endoscope revenues decreased because of the effects of foreign currency fluctuations. For the Life Care segment as a whole, revenues were below the level of the same quarter last year.

“New products of medical endoscopes will be introduced in North America during the second half of this year, and we expect topline to come back and start to grow again next year,” said Hiroshi Suzuki, chief executive officer of HOYA. “On the other hand, new products of intraocular lens are well received and gaining competitiveness. We look forward to its growth in the coming years.”

HOYA also announced the forecast for the first six months ending September 30, 2016 as shown below.

 
Revenue and Profit before tax   Three months ended   Variance
( Millions of Yen: Rounded off to the nearest million.)   Jun. 30,2015   Jun. 30,2016       (%)
Revenue 126,238   115,165   -8.8
Profit before tax 30,901 22,274 -27.9
Ratio of profit before tax(%) 24.5% 19.3%
Profit for the quarter 23,650 17,978 -24.0
Ratio of profit for the quarter(%)   18.7%   15.6%        
Profit attributable to owners of the Company 23,344 17,908 -23.3
Ratio of profit attributable to owners of the Company(%)   18.5%   15.5%        
Basic earnings per share (yen) 55.33 45.28
 
Projected Results for the First Half   Six months ended/ending   Variance
( Millions of Yen: Rounded off to the nearest million.)   Sep.30,2015   Sep.30,2016   (%)
Revenue 256,403   230,000 -10.3
Profit before tax 64,759 48,000 -25.9
Profit for the term 50,790 38,500 -24.2
Profit attributable to owners of the Company   50,381   38,500   -23.6
Profit for the term per share (Yen) 120.40 97.35

*Results are preliminary and unaudited.

The full reports are available at http://www.hoya.com

About HOYA

Founded in 1941 in Tokyo, Japan, Hoya is a global med-tech company and the leading supplier of innovative high-tech and medical products. Hoya is active in the fields of healthcare and information technology providing eyeglasses, medical endoscopes, intraocular lenses, optical lenses as well as key components for semiconductor devices, LCD panels and HDDs. With over 150 offices and subsidiaries worldwide, Hoya currently employs a multinational workforce of over 34,000 people. For more information, please visit http://www.hoya.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160729005417/en/

CONTACT

Hoya Group
Akiko Chiba, +81-3-6911-4824
Public Relation
Hoya-pr@hoya.com

同じカテゴリーの記事 

  • La Jolla Institute for Immunology and RevolKa started a Research Collaboration
  • U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
  • ESCMID Global 2024: Shionogi presents real-world data demonstrating efficacy of Fetcroja® / Fetroja® (cefiderocol) in critically ill patients with certain difficult-to-treat bacterial infections
  • Renesas’ New FemtoClock™ 3 Timing Solution Delivers Industry’s Lowest Power and Leading Jitter Performance of 25fs-rms
  • 成人向け予防接種プログラムは初期投資の19倍もの社会経済的価値をもたらすとの新レポートを発表